BioVie (BIVI)

• Market cap: $13.2M
• 1 day: -1.13%
• 5 days: -9.33%
• 1 month: -7.89%
• 3 months: -70.88%
• 6 months: -78.61%
• Year to date: -91.97%
• 1 year: -93.61%
• 5 years: -99.78%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Biotechnology

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13